Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Executive Summary

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

You may also be interested in...



US FDA’s Coronavirus Workload Shifting Beyond Idea Stage

Pre-IND inquiries are slowing and the FDA says more late-stage development work is coming.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Questions Remain On Gilead’s Remdesivir

Remdesivir shows ability to yield clinical improvement in moderately ill COVID-19 patients, but data are called ‘modest’ and shorter therapy duration showed better results than longer.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel